BeOne Medicines (NASDAQ:ONC) Issues Quarterly Earnings Results, Beats Expectations By $1.30 EPS

BeOne Medicines (NASDAQ:ONC) issued its quarterly earnings data on Thursday. The company reported $3.64 EPS for the quarter, beating analysts’ consensus estimates of $2.34 by $1.30, Zacks reports. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.76 billion.

Here are the key takeaways from BeOne Medicines’ conference call:

• Q3 revenue and profitability accelerated: Product revenue rose 33% year over year to about $1.9 billion, while GAAP operating income increased 157% to $419 million. BeOne raised its 2026 revenue outlook to $6.9 billion–$7.0 billion and increased its operating-income guidance.
• BRUKINSA continued to drive growth: Global sales grew 34% to $1.4 billion, with U.S. sales exceeding $1 billion for the first time. Management pointed to strong new-patient starts and real-world evidence, while noting that U.S. sales benefited by about $50 million from order timing.
• Pipeline progress broadened across hematology and solid tumors: BeOne reported encouraging early data for several solid-tumor programs and advanced its B7-H4 ADC into a Phase III trial. The company also said its BTK degrader met the primary endpoint in a Phase II CLL study and that its treatment-naive mantle-cell lymphoma application received FDA priority review.
• Some expected returns may take longer, and investment will remain high: After FDA discussions, BeOne shifted its planned accelerated-approval filing for the BTK degrader in relapsed/refractory CLL to mid-2027, citing a request for additional follow-up. Management expects 2027 operating-expense growth to remain substantial, moderating the pace of margin expansion; it also flagged potential revenue pressure for XGEVA and KYPROLIS from biosimilars and possible China VBP inclusion.

BeOne Medicines Price Performance

Shares of ONC stock traded up $21.90 during trading hours on Friday, reaching $409.15. The company’s stock had a trading volume of 567,204 shares, compared to its average volume of 318,554. BeOne Medicines has a fifty-two week low of $253.95 and a fifty-two week high of $409.80. The firm’s 50 day simple moving average is $362.80 and its 200-day simple moving average is $325.98. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $44.92 billion, a price-to-earnings ratio of 72.00 and a beta of 0.63.

Insiders Place Their Bets

In related news, insider Xiaodong Wang sold 38,287 shares of the company’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $349.10, for a total transaction of $13,365,991.70. Following the completion of the sale, the insider directly owned 6,079 shares in the company, valued at $2,122,178.90. This represents a 86.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Oyler sold 115,011 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $357.87, for a total value of $41,158,986.57. Following the sale, the chief executive officer owned 125,799 shares of the company’s stock, valued at approximately $45,019,688.13. This represents a 47.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 376,373 shares of company stock worth $134,848,154 over the last 90 days. Corporate insiders own 6.19% of the company’s stock.

More BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q3 results topped estimates and revenue guidance was raised. BeOne reported adjusted EPS of $3.64 versus the $2.34 consensus and revenue of $1.89 billion versus $1.76 billion expected. The company also raised its 2026 revenue guidance, signaling stronger business expectations. BeOne Q3 earnings and guidance
• Positive Sentiment: FDA granted priority review to a BRUKINSA combination. The review concerns use in first-line mantle cell lymphoma; a label expansion could broaden the drug’s potential market if approved. FDA priority review for BRUKINSA
• Positive Sentiment: Analysts raised their price targets and maintained positive ratings. Barclays lifted its target to $446 with an “overweight” rating; Citizens JMP raised its target to $463 and kept “market outperform”; Wells Fargo raised its target to $435 and retained “overweight.” The revisions reflect improved analyst expectations, though targets are not guarantees of future performance. Barclays rating information Citizens JMP rating information Wells Fargo rating information

Wall Street Analysts Forecast Growth

ONC has been the topic of several recent research reports. Wells Fargo & Company raised their target price on shares of BeOne Medicines from $400.00 to $435.00 and gave the stock an “overweight” rating in a report on Friday. JPMorgan Chase & Co. boosted their price target on BeOne Medicines from $425.00 to $445.00 and gave the company an “overweight” rating in a research note on Thursday, October 1st. Truist Financial reissued a “buy” rating and set a $448.00 price target (up from $420.00) on shares of BeOne Medicines in a research report on Friday. Morgan Stanley restated an “overweight” rating and set a $425.00 price objective on shares of BeOne Medicines in a research note on Friday, October 16th. Finally, Citizens Jmp raised their price objective on BeOne Medicines from $405.00 to $463.00 and gave the stock a “market outperform” rating in a research note on Friday. Sixteen equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $434.79.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.